Prelude Therapeutics Inc
PRLD0.854USD
+0.026+3.10%
시장 운영 시간 （ET）시세는 15분 지연됩니다
48.21M시가총액
손실P/E TTM
자세한 내용은 Prelude Therapeutics Inc 회사
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.
회사 정보
종목 코드 PRLD
회사 이름Prelude Therapeutics Inc
상장일Sep 25, 2020
CEODr. Krishna (Kris) Vaddi, Ph.D.
직원 수131
유형Ordinary Share
회계 연도 종료Sep 25
주소175 Innovation Boulevard
도시WILMINGTON
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호19805
전화13024671280
웹사이트https://preludetx.com/
종목 코드 PRLD
상장일Sep 25, 2020
CEODr. Krishna (Kris) Vaddi, Ph.D.
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Krishna (Kris) Vaddi, Ph.D.
Dr. Krishna (Kris) Vaddi, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
3.67M
+29.33%
Dr. Paul A. Friedman, M.D.
Dr. Paul A. Friedman, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
500.10K
--
Dr. Andrew P. Combs, Ph.D.
Dr. Andrew P. Combs, Ph.D.
Chief Chemistry Officer
Chief Chemistry Officer
480.12K
+27.99%
Dr. Peggy A. Scherle, Ph.D.
Dr. Peggy A. Scherle, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
185.69K
+2.77%
Dr. Jane Huang, M.D.
Dr. Jane Huang, M.D.
President, Chief Medical Officer
President, Chief Medical Officer
90.27K
+7.15%
Ms. Mardi C. Dier
Ms. Mardi C. Dier
Independent Director
Independent Director
10.00K
--
Dr. Paul Scherer, M.D.
Dr. Paul Scherer, M.D.
Independent Director
Independent Director
--
--
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Independent Director
Independent Director
--
--
Mr. Bryant D. Lim, J.D.
Mr. Bryant D. Lim, J.D.
Chief Financial Officer, Chief Legal Officer, Corporate Secretary
Chief Financial Officer, Chief Legal Officer, Corporate Secretary
--
--
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Krishna (Kris) Vaddi, Ph.D.
Dr. Krishna (Kris) Vaddi, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
3.67M
+29.33%
Dr. Paul A. Friedman, M.D.
Dr. Paul A. Friedman, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
500.10K
--
Dr. Andrew P. Combs, Ph.D.
Dr. Andrew P. Combs, Ph.D.
Chief Chemistry Officer
Chief Chemistry Officer
480.12K
+27.99%
Dr. Peggy A. Scherle, Ph.D.
Dr. Peggy A. Scherle, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
185.69K
+2.77%
Dr. Jane Huang, M.D.
Dr. Jane Huang, M.D.
President, Chief Medical Officer
President, Chief Medical Officer
90.27K
+7.15%
Ms. Mardi C. Dier
Ms. Mardi C. Dier
Independent Director
Independent Director
10.00K
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Sun, Jul 27
마지막 업데이트: Sun, Jul 27
주주
주주 유형
주주
주주
비율
OrbiMed Advisors, LLC
25.02%
Baker Bros. Advisors LP
23.20%
Vaddi (Krishna)
8.41%
Boxer Capital Management, LLC
4.83%
The Vanguard Group, Inc.
2.31%
Other
36.22%
주주
주주
비율
OrbiMed Advisors, LLC
25.02%
Baker Bros. Advisors LP
23.20%
Vaddi (Krishna)
8.41%
Boxer Capital Management, LLC
4.83%
The Vanguard Group, Inc.
2.31%
Other
36.22%
주주 유형
주주
비율
Hedge Fund
31.09%
Private Equity
25.02%
Individual Investor
11.38%
Investment Advisor
9.38%
Investment Advisor/Hedge Fund
3.57%
Research Firm
0.70%
Venture Capital
0.06%
Bank and Trust
0.04%
Pension Fund
0.01%
Other
18.77%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
158
35.42M
81.22%
-13.38M
2025Q1
169
35.41M
81.20%
-13.64M
2024Q4
176
41.97M
99.49%
-4.74M
2024Q3
176
39.67M
94.09%
-11.21M
2024Q2
173
43.50M
103.37%
-2.47M
2024Q1
184
38.12M
90.60%
-8.41M
2023Q4
190
38.61M
71.39%
-9.45M
2023Q3
202
40.53M
76.60%
-4.90M
2023Q2
201
43.54M
105.11%
+2.58M
2023Q1
203
37.45M
102.57%
-2.14M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
OrbiMed Advisors, LLC
10.91M
25.02%
--
--
Mar 31, 2025
Baker Bros. Advisors LP
10.12M
23.2%
-5.19K
-0.05%
Jun 12, 2025
Vaddi (Krishna)
3.67M
8.41%
+832.02K
+29.33%
Mar 31, 2025
Boxer Capital Management, LLC
2.11M
4.83%
+399.83K
+23.41%
Mar 31, 2025
The Vanguard Group, Inc.
1.01M
2.31%
-1.19K
-0.12%
Mar 31, 2025
T. Rowe Price Associates, Inc.
959.30K
2.2%
-53.05K
-5.24%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
919.00K
2.11%
-14.36K
-1.54%
Mar 31, 2025
Renaissance Technologies LLC
656.70K
1.51%
+22.20K
+3.50%
Mar 31, 2025
Acadian Asset Management LLC
529.33K
1.21%
+43.95K
+9.05%
Mar 31, 2025
Friedman (Paul A)
500.10K
1.15%
--
--
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
Dimensional US Core Equity 1 ETF
0%
iShares Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
ProShares Ultra Nasdaq Biotechnology
0%
Schwab U.S. Small-Cap ETF
0%
Schwab U.S. Broad Market ETF
0%
iShares Micro-Cap ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
더 보기
Dimensional US Core Equity 1 ETF
비율0%
iShares Russell 2000 ETF
비율0%
Proshares Ultra Russell 2000
비율0%
ProShares UltraPro Russell2000
비율0%
ProShares Ultra Nasdaq Biotechnology
비율0%
Schwab U.S. Small-Cap ETF
비율0%
Schwab U.S. Broad Market ETF
비율0%
iShares Micro-Cap ETF
비율0%
Invesco Nasdaq Biotechnology ETF
비율0%
iShares Core S&P Total U.S. Stock Market ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
